PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 107 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is 20.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $519,000 | -39.6% | 136,609 | -19.1% | 0.00% | – |
| Q4 2019 | $859,000 | -3.6% | 168,948 | -4.2% | 0.00% | – |
| Q3 2019 | $891,000 | -77.3% | 176,394 | -72.3% | 0.00% | – |
| Q2 2019 | $3,928,000 | +5280.8% | 636,954 | +3957.0% | 0.00% | – |
| Q1 2019 | $73,000 | -97.3% | 15,700 | -97.6% | 0.00% | -100.0% |
| Q4 2018 | $2,746,000 | -35.8% | 653,774 | -4.1% | 0.00% | 0.0% |
| Q3 2018 | $4,275,000 | -46.1% | 681,667 | -30.9% | 0.00% | -66.7% |
| Q2 2018 | $7,928,000 | -52.2% | 986,091 | -55.6% | 0.00% | -50.0% |
| Q1 2018 | $16,585,000 | +601.6% | 2,223,284 | +459.5% | 0.01% | – |
| Q4 2017 | $2,364,000 | +0.1% | 397,401 | +23.9% | 0.00% | – |
| Q3 2017 | $2,361,000 | +150.9% | 320,679 | +131.4% | 0.00% | – |
| Q2 2017 | $941,000 | -66.7% | 138,600 | -53.6% | 0.00% | -100.0% |
| Q1 2017 | $2,823,000 | -4.5% | 299,023 | -12.6% | 0.00% | 0.0% |
| Q4 2016 | $2,955,000 | +655.8% | 342,016 | +454.5% | 0.00% | – |
| Q3 2016 | $391,000 | +55.8% | 61,678 | +3.8% | 0.00% | – |
| Q2 2016 | $251,000 | -72.4% | 59,400 | -71.5% | 0.00% | – |
| Q1 2016 | $909,000 | -1.1% | 208,526 | +39.3% | 0.00% | – |
| Q4 2015 | $919,000 | -7.5% | 149,736 | -13.8% | 0.00% | – |
| Q3 2015 | $994,000 | -56.7% | 173,742 | -43.5% | 0.00% | -100.0% |
| Q2 2015 | $2,294,000 | -5.4% | 307,476 | -24.1% | 0.00% | 0.0% |
| Q1 2015 | $2,424,000 | -25.5% | 405,281 | -5.9% | 0.00% | 0.0% |
| Q4 2014 | $3,255,000 | +34.6% | 430,488 | -7.6% | 0.00% | – |
| Q3 2014 | $2,418,000 | +95.6% | 465,936 | +62.5% | 0.00% | – |
| Q2 2014 | $1,236,000 | -27.1% | 286,812 | -30.8% | 0.00% | – |
| Q1 2014 | $1,696,000 | -2.8% | 414,641 | +26.7% | 0.00% | – |
| Q4 2013 | $1,744,000 | +167.1% | 327,340 | +151.9% | 0.00% | – |
| Q3 2013 | $653,000 | +324.0% | 129,957 | +276.7% | 0.00% | – |
| Q2 2013 | $154,000 | – | 34,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|